Please assess the completion status of the following clinical trial:

Trial Title: Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Patients age \> 18 years and ≤ 75 years~* Body weight 50 to 100 kg~* Chronic hand dermatitis (duration \> 6 months)~* Atopic constitution according to~  * Erlanger Atopiescore1 and/or~ * positive personal history for atopic eczema, allergic rhinitis, allergic asthma and/or~ * elevated serum IgE~* Severe hand dermatitis not responding to treatment with potent topical steroids for at least 4 weeks within the past 6 months due to IGA~* Written informed consent~Exclusion Criteria:~* Participation in other clinical trial within past 4 weeks~* Pregnancy/breastfeeding~* Women within reproductive age except those women who fulfil at least one of the following criteria throughout the total study and until at least 5 weeks after active study treatment in case of early study termination:~* post-menopausal women (12 months physiological amenorrhoea or 6 months amenorrhoea with serum FSH level \> 40 mlU/ml),~* postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy)~* Regular and proper use of at least two methods of contraception, including at least one method of contraception with a failure rate \<1% per year (eg, implants, depot preparations, oral contraceptives, IUD).~* vasectomy of the partner.~* Women within reproductive age, who do not meet all of the following criteria throughout the whole study or - in case of early study termination - up to 5 weeks after active therapy:~* The patient understands the teratogenic risk associated with taking the study medication.~* The patient understands the need for strict monthly monitoring, the need for a reliable, continuous contraception and the need for regular pregnancy tests throughout the study and - in case of early study termination - up to 5 weeks of active therapy.~* The patient is able to adequately and reliably apply methods of contraception.~* The patient is informed about the possible consequences of pregnancy and knows that she must immediately contact her physician in case of suspected pregnancy.~* The patient gives informed consent about knowing the potential risks and necessary measures to avoid pregnancy.~* Blood and/or plasma donation during the whole study period. In case of early study termination blood and plasma donation is not allowed until 1 month after the end of active study treatment~* UV-therapy within past 3 months~* Concurrent photo-and / or photochemotherapy~* Known Hypersensitivity / Intolerance against ciclosporin, alitretinoin or any other ingredients of Immunosporin® or Toctino®~* Known Allergy against peanuts or soya~* Known Hereditary fructose intolerance~* Acute and/or uncontrolled chronic infectious disease~* Known Congenital or acquired immune deficiency~* Malignant tumor (past or present)~* Uncontrolled arterial hypertension (RR systolic ≥ 160 mm Hg and/or RR diastolic≥ 90 mm Hg despite anti-hypertensive treatment)~* Renal insufficiency (Serum creatinine above normal range)~* Liver insufficiency (CHILD ≥ Stadium B)~* Not sufficiently controlled hyperlipidemia (LDL/HDL ratio \> 4 despite medical treatment)~* Clinically significant thyroid hypofunction~* Known Hypervitaminosis A~* Concurrent supplementation of vitamin A or treatment with other retinoids~* Concurrent tetracycline therapy~* Concurrent therapy with St. John's wort (Johanniskraut)~* Known genetic diseases causing increased UV light sensitivity such as Xeroderma pigmentosum, Cockayne-syndrome, Bloom syndrome~* Known Drug- and/or alcohol abuse~* Known significant psychiatric morbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ciclosporingroup (Type: ACTIVE_COMPARATOR): None
- Alitretinoingroup (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).